High grade glioma, Diffuse intrinsic pontine glioma
Conditions
Interventions
The patient is intradermally injected with 0.5-2.0 mg of the HLA-A*2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMN), HLA-A*0201-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMN
Sponsors
Osaka University Graduate School of Medicine Pediatrics
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed as malignant glioma or diffuse intrinsic glioma 2. Performance status (ECOG) 0-3 3. Meet the following criteria for organ functions Neutrophil more than 1,000/microliter, Platelet more than 25,000/microliter, Hemoglobin more than 6.5 g/dl Serum creatinine less than 2.0 mg/dL Serum bilirubin less than 3 folds of the upper normal limit Serum AST/GOT less than 3 folds of the upper normal limit Serum Albumin more than 2.5g/dl Arterial oxygen saturation more than 94% in room air 4. Informed consent has been obtained from legal guardian. 5. HLA 2402 and or 0201 6. WT1 expression in malignant cells in high grade glioma
Exclusion criteria
Exclusion criteria: 1. There is deep-seated active infection. 2. There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis. 3. Patients who have complications that are considered inappropriate for the trial. 4. There are other malignancies. 5. There are hematopoietic stem cell disorders such as MDS. 6. Post allogeneic hematopoietic stem cell transplantation 7. Responsible doctors judged the patient inappropriate for the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safty | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival time all over survival time Immunomonitering | — |
Countries
Japan
Contacts
Public ContactYoshiko Hashii
Osaka University Graduate School of Medicine Pediatrics
Outcome results
None listed